First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial
出版年份 2018 全文链接
标题
First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial
作者
关键词
Ribociclib, Advanced breast cancer, MONALEESA-2, CDK4/6
出版物
BREAST CANCER RESEARCH AND TREATMENT
Volume 169, Issue 3, Pages 469-479
出版商
Springer Nature
发表日期
2018-02-05
DOI
10.1007/s10549-017-4658-x
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial
- (2016) N. Harbeck et al. ANNALS OF ONCOLOGY
- The PI3K/AKT Pathway as a Target for Cancer Treatment
- (2016) Ingrid A. Mayer et al. Annual Review of Medicine
- Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer
- (2016) Sonya C. Tate et al. EUROPEAN JOURNAL OF CANCER
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abstract 4756: In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer
- (2015) Neil A. O'Brien et al. CANCER RESEARCH
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†
- (2014) F. Cardoso et al. ANNALS OF ONCOLOGY
- Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6- Reactivating Rb in cancer.
- (2014) S. Kim et al. MOLECULAR CANCER THERAPEUTICS
- Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition
- (2012) Michael Gnant Expert Review of Anticancer Therapy
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- The Role of Mammalian Target of Rapamycin (mTOR) Inhibition in the Treatment of Advanced Breast Cancer
- (2012) Michael Gnant Current Oncology Reports
- Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer
- (2012) Emily M. Fox et al. Frontiers in Oncology
- ER -Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
- (2011) T. W. Miller et al. Cancer Discovery
- Mechanisms of Endocrine Resistance in Breast Cancer
- (2010) C. Kent Osborne et al. Annual Review of Medicine
- Residual cancer burden in locally advanced breast cancer: a superior tool
- (2008) Zeina Ahmad Nahleh Current Oncology
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now